创新药走强，科创创新药ETF（589720）涨超2%，“924行情”以来跑赢主要港股创新药指数，资金积极布局，连续3日净流入

Core Viewpoint - The market is shifting focus from interim report performance to new directions, with optimism for innovative drugs, overseas expansion, and the clearing of centralized procurement sectors in the second half of 2025 [1] Group 1: Innovative Drugs - China's innovative drugs are entering a stage of result realization, with significant R&D progress that is not affected by trade frictions, expected to remain a key investment theme in the pharmaceutical sector for 2025 [1] - The Guotai ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking an index of 30 representative high-quality companies, primarily in high-growth biotech [1] Group 2: Performance Metrics - Since the "924 market" rally, the Sci-Tech Innovation Drug Index has outperformed major Hong Kong innovative drug indices, with returns from September 24, 2024, to June 30, 2025, showing increases of 75% for the Sci-Tech Innovation Drug Index, compared to 70% for both the Hong Kong innovative drug index and the Hang Seng Hong Kong Stock Connect innovative drug index [1] - The Sci-Tech Innovation Drug Index may provide better exposure to the elasticity of the Sci-Tech Innovation Board during periods of rising market risk appetite [1]